Valuation: Asahi Kasei Corporation

Market Cap 2,052B 12.84B 11.69B 10.83B 9.79B 18.37B 1,199B 19.23B 131B 51.91B 648B 48.16B 47.15B P/E 2027 *
11.6x
P/E 2028 * 11.1x
Enterprise Value 2,721B 17.02B 15.51B 14.36B 12.99B 24.36B 1,590B 25.5B 174B 68.84B 859B 63.86B 62.52B EV / Sales 2027 *
0.81x
EV / Sales 2028 * 0.78x
Free-Float
95.42%
Yield 2027 *
2.99%
Yield 2028 * 3.36%
11-13 Asahi Kasei Homes Launches 12.88 Billion Yen Tender Offer for Mori-Gumi MT
11-12 Asahi Kasei, Circularise, And Furuya Metal Launch Demonstration Project For Precious Metal Traceability In Chlor-Alkali Electrolysis Electrodes CI
11-05 Asahi Kasei Posts Higher Fiscal H1 Attributable Income; Revenue Up MT
11-05 Asahi Kasei Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027 CI
11-05 Asahi Kasei Corporation Announces Dividend for the Second Quarter End of Fiscal Year Ending March 31, 2027, Payable on December 1, 2026; Revises Dividend Guidance for the Full Fiscal Year Ending March 31, 2027 CI
11-05 Asahi Kasei Corporation Reports Earnings Results for the Half Year Ended September 30, 2026 CI
11-04 Asahi Kasei Signs Memorandum of Understanding with Power to Hydrogen to Accelerate Commercialization of Anion Exchange Membrane Water Electrolysis for Clean Hydrogen Production CI
10-23 Asahi Kasei Pins Its Growth on Electronic Materials Zonebourse
10-10 Asahi Kasei Therapeutics, Inc. Announces FDA Approval Of HOVILPRI Tablets Developed By AiCuris Anti-Infective Cures AG For Mucocutaneous HSV Lesions Refractory To Standard Antiviral Treatment In Immunocompromised Adults CI
10-10 US FDA approves Asahi Kasei's drug for persistent herpes infections RE
10-09 Japan's Nikkei limps to weekly loss as AI doubts, bond stress weigh RE
10-08 Asahi Kasei Therapeutics Announces First Patient Dosed in Phase 2a Trial of AIC468 for BK Virus Infection in Kidney Transplant Recipients CI
10-01 Teijin Frontier, Asahi Kasei Advance Merge to Form TA Frontier MT
1 day-3.51%
1 week-8.95%
Current month-7.48%
1 month-6.34%
3 months-9.15%
6 months-11.29%
Current year+6.88%
1 week 1,477.5
Extreme 1477.5
1,642.5
1 month 1,474
Extreme 1474
1,660
Current year 1,415
Extreme 1415
1,906
1 year 1,247
Extreme 1247
1,906
3 years 880
Extreme 880
1,906
5 years 880
Extreme 880
1,906
10 years 606.1
Extreme 606.1
1,906
Manager TitleAgeSince
Director of Finance/CFO - -
President 67 01/04/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 71 01/04/2022
Director/Board Member 79 01/06/2018
Director/Board Member 67 01/06/2021
Change 5-day change 1-year change 3-year change Capi.($)
-3.51%-8.95%+14.24%+47.42% 12.84B
-4.21%-7.17%+19.42%+2.62% 62.8B
-1.00%-6.92%+17.59%+14.44% 47.89B
+1.49%+5.13%+7.72%+29.17% 17.24B
-0.72%+0.24%+19.71%-24.50% 9.12B
-4.19%-8.89%+18.12%+3.40% 8.78B
-1.73%-3.65%+12.19% - 8.57B
-3.23%-12.92%+62.34%-9.10% 7.43B
+0.48%+2.02%-11.47%+8.42% 7.98B
-4.26%-7.25%+26.34%+15.20% 5.62B
Average -2.09%-4.39%+18.62%+9.67% 19B
Weighted average by Cap. -2.23%-4.72%+17.75%+10.34%

Financials

2027 *2028 *
Net sales 3,370B 21.08B 19.21B 17.78B 16.08B 30.17B 1,969B 31.58B 215B 85.25B 1,064B 79.09B 77.43B 3,407B 21.31B 19.42B 17.97B 16.26B 30.5B 1,990B 31.92B 217B 86.18B 1,075B 79.95B 78.27B
Net income 179B 1.12B 1.02B 943M 853M 1.6B 104B 1.67B 11.4B 4.52B 56.43B 4.19B 4.11B 186B 1.16B 1.06B 980M 887M 1.66B 109B 1.74B 11.85B 4.7B 58.66B 4.36B 4.27B
Net Debt 669B 4.19B 3.81B 3.53B 3.19B 5.99B 391B 6.27B 42.67B 16.93B 211B 15.7B 15.37B 619B 3.87B 3.52B 3.26B 2.95B 5.54B 361B 5.8B 39.44B 15.65B 195B 14.51B 14.21B
Projected Income Statement - Annual - Asahi Kasei Corporation
Logo Asahi Kasei Corporation
Asahi Kasei Corp is a Japan-based company mainly engaged in the materials business, housing business and healthcare business. The Company operates through three business segments. The Materials segment provides styrene monomer, acrylonitrile, polyethylene, automotive-related fibers, electronic materials, mixed signal large scale integrated circuits (LSI), hall elements, deep ultraviolet light-emitting diodes (LEDs), pharmaceutical and food additives and others. The Housing segment provides construction contracting, renovation and other housing-related business, as well as lightweight aerated concrete (ALC), insulation materials and others. The Healthcare segment provides medical drugs, hemodialysis and apheresis related equipment, virus removal filters, cardiopulmonary resuscitation-related products and others. The Company also provides plant engineering, environmental engineering, various research and information provision businesses, and personnel dispatch and introduction services.
Employees
47,895
Date Price Change Volume
20/11/26 JP¥1,484.50 -3.51% 2,992,000
19/11/26 JP¥1,538.50 -1.00% 3,713,900
18/11/26 JP¥1,554.00 -1.99% 4,662,300
17/11/26 JP¥1,585.50 -1.28% 3,467,100
16/11/26 JP¥1,606.00 -1.50% 3,017,700
Trader
Investor
Global
Quality
ESG MSCI
AAA
MarketScreener Ratings - Asahi Kasei Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
1,538.50JPY
Average target price
1,948.18JPY
Spread / Average Target
+26.63%
  1. Stock Market
  2. Stocks
  3. 3407 Stock